Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
608 injection in moderate-to-severe plaque psoriasis (China, phase 3)
CTR20222943Phase 3Completed
- Sponsor
- Henlius
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing 608 active treatment with Placebo (608 matching placebo) (2 arms). Started Nov 2022; status: completed.
02
Drugs
608
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20222943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222943.